FHI Clinical to write clinical trial protocol for development of Gb Sciences’ COVID-19-aelated, anti-inflammatory therapies
LAS VEGAS — Gb Sciences, a leading plant-inspired, biopharmaceutical research and drug development company, announces that FHI Clinical will consult on Gb Sciences’ go-to-market strategy for its COVID-19-related, anti-inflammatory therapeutics and, ultimately, write Gb Sciences’ draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations. FHI Clinical has supported 23 COVID trials,
